Application of FibroScan 502 controlled attenuation parameters in monitoring of risk factors in nonalcoholic fatty liver diseases

doi:10.3969/j.issn.1002-7386.2018.01.012

Abstract：Objective To investigate the clinical value of controlled attenuation parameter (CAP) in monitoring the outcome of nonalcoholic fatty liver diseases (NAFLD) by monitoring the CAP and risk factors of NAFLD for 2 years in physical examination population by means of FibroScan 502.Methods A total of 528 subjects who underwent health examination in our hospital were enrolled in the study.The degree of fatty liver of these subjects was detected according to CAP by using FibroScan 502,and the medical history,drinking history,body weight,height,the serum levels of alanine aminotransferase (ALT),aspartate aminotransferase (AST),fasting blood glucose (FBS),uric acid (UA),total cholesterol (CHO),triglyceride (TG),thyroid hormone (FT3,FT4,TSH),growth hormone were dtected and compared between two groups.The subjects were grouped according to the changes of body weight,and the Kruskal Wallis H rank sum test was used to analyze statistically the data among the groups.Results According to the changes of body weight on the second year,these subjects were divided into 7 groups,weight loss≥12.5％ as group 3,7.5％ ≤weight loss ＜ 12.5％ as group 2,2.5％ ≤ weight loss ＜7.5％ as group 1,weight increase or decrease less than 2.5％ as group 0,2.5％ ≤weight increase ＜7.5％ as group 1 +,7.5％ ≤weight increase ＜ 12.5％ as group 2 +,weight increase ≥ 12.5％ as group 3 +.The levels of CAP,FBS,UA,ALT were changed with body weight (P ＜ 0.05),however,the levels of AST,CHO,TG,thyroid hormone,growth hormone did not change with body weight significantly (P ＞ 0.05).Conclusion The obesity is closely related with NAFLD.The levels of CAP,FBS,UA,ALT are changed with body weight,which suggests that the CAP detected by FibroScan 502 combined with biochemical indicators can dynamically monitor the pathogenesis,development and prognosis of NAFLD.